Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Hong Kong-based Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program AI drug discovery collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceutical (CTFH), taking on previously undruggable targets. 9 October 2019
Biotechnology
A new research collaboration between Danish diabetes giant Novo Nordisk and the Cambridge, USA-based firm bluebird bio will see the companies work together on certain in vivo gene editing technologies. 9 October 2019
Biotechnology
Collaboration will be crucial to keeping up with growing consumer demand for microbiome support, writes David Evendon-Challis, vice president of innovation at the consumer goods firm, RB, in an Expert View piece. 9 October 2019
Biotechnology
The US regulator has finally approved Scenesse (afamelanotide), a subcutaneous implant used to treat the ultra-rare disorder erythropoietic protoporphyria, in which exposure to sunlight causes pain. 9 October 2019
Biotechnology
UK-based biotech firm Prokarium says it has received an investment of £4.59 million ($5.6 million) from the Wellcome Trust to fund two clinical trials of its lead program, Entervax, a bivalent vaccine against enteric fever. 9 October 2019
Biotechnology
Basel-based drugmaker Novartis has provided a detailed look at the data propelling late stage development of ligelizumab, a possible replacement for the ageing respiratory drug Xolair (omalizumab). 8 October 2019
Biotechnology
The growing stable of Flagship Pioneering now has another member, with this one purportedly the world’s first exoneural biology company. 8 October 2019
Biotechnology
GlaxoSmithKline today announced a five-year collaboration with California, USA-based biotech Lyell Immunopharma, to develop new technologies to improve cell therapies for cancer patients. 8 October 2019
Biotechnology
Handan He has left her role as global head of computational, biopharmaceutics and translational PK/PD at Novartis’ pharma unit to join Ascletis as chief scientific officer. 8 October 2019
Biotechnology
There were two important drug approvals for medicines regulator Health Canada today, the first being US biotech major Amgen’s new humanized anti-sclerostin monoclonal antibody for osteoporosis. 8 October 2019
Biotechnology
US biotech major Gilead Sciences yesterday announced that the New Drug Application (NDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis (RA), has been submitted to the Japanese Ministry of Health, Labor and Welfare (MHLW). 8 October 2019
Biotechnology
Shares in South Korean biotech Helixmith are up by more than half after the firm announced results for a first-in-class biologic, VM202. 8 October 2019
Biotechnology
With its leading ophthalmology drug Lucentis (ranibizumab) nearing the end of its patent exclusivity, there was good news for Swiss pharma giant Novartis with US regulatory approval for its successor. 8 October 2019
Biotechnology
US biotech Sarepta Therapeutics lost more than 50% of its market value between mid-July and last week, with an adverse event report and a US Food and Drug Administration (FDA) rejection of Vyondys 53 (golodirsen) contributing to the damage. 7 October 2019
Biotechnology
A drug being investigated in a charity-led program could overcome resistance found in aggressive breast cancers, a study has suggested. 7 October 2019
Biotechnology
Shares of Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals, leapt 22.3% to $18.50 in pre-market trading today, after the companies revealed a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with US pharma giant Pfizer 7 October 2019
Biotechnology
San Diego, California-based Prometheus Biosciences has entered into a global, multi-target strategic collaboration with Japan’s Takeda Pharmaceutical to discover, develop, and commercialize novel therapies for inflammatory bowel disease (IBD). 7 October 2019
Biotechnology
Phathom Pharmaceuticals has announced that Terrie Curran will be appointed chief executive effective upon the closing of the acquisition of Celgene Corp by Bristol-Myers Squibb, 4 October 2019
Biotechnology
The Roche therapy Ocrevus (ocrelizumab) was only approved in 2017, but it has already become the multiple sclerosis (MS) market leader in its class, recording sales of $1.72 billion in the first half of 2019. 4 October 2019
Biotechnology
The UK’s reimbursement agency has provided draft guidance against reimbursing Roche’s Tecentriq (atezolizumab) plus chemo in triple-negative breast cancer (TNBC). 4 October 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze